As of Mar 31, 2025
iShares Genomics Immunology and Healthcare ETF (ARCA: IDNA)
Ticker | Name | Share % | |
---|---|---|---|
SM | Roche Holding A.G. | 5.49% | |
GILD | Gilead Sciences Inc | 4.62% | |
SRPT | Sarepta Therapeutics Inc | 4.53% | |
RVMD | Revolution Medicines Inc Ser C Pc Pp | 4.44% | |
INCY | Incyte Corp. | 4.30% | |
REGN | Regeneron Pharmaceuticals, Inc. | 4.23% | |
EXEL | Exelixis Inc | 5.05% | |
TK | Takeda Pharmaceutical Co Ltd | 4.95% | |
PA | Sanofi SA | 5.54% | |
HK | Beigene, Ltd. | 6.57% | |
SWTX | Springworks Therapeutics Inc | 4.73% | |
LN | GSK plc | 5.40% | |
CO | Genmab A.S. | 4.33% | |
MRK | Merck & Co. Inc. | 4.26% |
The IDNA ETF is currently trading at $20.67, which represents a -1.67% change. Over the past 52 weeks, the ETF has traded as high as $25.80 and as low as $17.26.
The expense ratio of IDNA is 0.47%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for IDNA is 111.77M. This represents the total market value of the assets managed by the ETF.
IDNA follows a Mid Cap Growth investment style.
The top holdings of IDNA include: SM (5.49%), GILD (4.62%), SRPT (4.53%), RVMD (4.44%), INCY (4.3%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for IDNA is currently not available.